Edasalonexent was a potential treatment for preserving muscle function in patients with Duchenne muscular dystrophy. However, in the trial – PolarisDMD – it did not show effectiveness.
Sadly, this means that the development of edasalonexent, including the ongoing GalaxyDMD open-label extension trial, will be stopped.
Catabasis, the company that manufactures edasalonexent, has provided more information in a letter to the Duchenne community.
We are here for you. Please contact our helpline on 0800 652 6352 or email firstname.lastname@example.org if you have any queries or concerns about this news.